HER2 in prostate cancer - A viable target of innocent bystander?

Journal of the National Cancer Institute

Volumn 92, Issue 23, 2000, Pages 1866-1868

  Scher, Howard I ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BIOLOGICAL MARKER; CANCER ANTIBODY; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENE PRODUCT; KI 67 ANTIGEN; LIGAND; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE; RNA; TRASTUZUMAB; UNCLASSIFIED DRUG;

BASAL CELL; BREAST CANCER; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOTOXICITY; DIAGNOSTIC TEST; DRUG SPECIFICITY; DRUG TARGETING; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GENE OVEREXPRESSION; HEALTH CARE COST; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR BIOLOGY; ONCOGENE NEU; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TARGET ORGAN; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR GROWTH;

EID: 0034614093     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.23.1866     Document Type: Editorial

References (30)

1. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways
2. Genetic basis and clonal evolution of human prostate cancer
3. Clinical states in prostate cancer: Toward a dynamic model of disease progression
4. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
5. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)
6. HER-2/neu (c-erb-B2) gene and protein in breast cancer
7. HER2: A 'predictive factor' ready to use in the daily management of breast cancer patients?
8. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy
9. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
10. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer
11. Her-2-neu expression and progression toward androgen independence in human prostate cancer
12. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma
13. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer
14. Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas
15. C-erbB-2 oncoprotein: A potential biomarker of advanced prostate cancer
16. Expression of NEU/HER-2 oncoprotein (p185neu) in prostate tumors: An immunohistochemical study
17. Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas
18. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization
19. HER-2/neu membrane overexpression in prostate cancer (PC)
20. A phase II trial of herceptin alone and with taxol for the treatment of prostate cancer
21. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process
22. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
23. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy
24. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays
25. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms
26. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells
27. The use of HER2 testing in the management of breast cancer
28. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases
29. Synergistic anti-tumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents
30. Differential anti-tumor effects of targeting distinct epitopes of the Her-2/neu extracellular domain in xenograft models of prostate cancer